eli lilly & co s tirzepatide Finds Yet Another Condition for Zepbound to Treat. The Stock Is Up Eli Lilly just issued a

Conversely, if someone on compounded tirzepatide says they draw 50 units, you need to know their vial concentration

Studies show SGLT2 Inhibitors may have the following benefits: Shown to extend lifespan in mice May reduce inflammation and oxidative stress May lower HbA1c May improve cardiovascular health and kidney health May lower the risk of dementia and Parkinsons May eliminate senescent cells May encourage moderate weight loss Though both Invokana (Canagliflozin) and Brenzavvy (Bexagliflozin) work in the same way, Invokana has more years of research supporting its potential benefits, while Brenzavvy is a relatively new SGLT2 that may show similar longevity benefits

The weekly monitoring can catch problems early before they become reasons to discontinue treatment

Patches eliminate the need for needles and daily dosing schedules, though they do require a four-hour wear window and battery management

Couderc R, et al

Add 1-3 servings of fruit daily, like berries with breakfast or an apple with lunch